Loading
ALK Positive Non Small Cell Lung Cancer (NSCLC) / NVL-655 / Non Small Cell Lung Cancer · Interventional Study
ClinicalTrials.gov · September 4, 2026
The material analysed did not support any firm read.
This is a registry record for an expanded access program (compassionate use pathway) offering investigational neladalkib to patients with ALK-positive advanced NSCLC or other ALK-positive solid tumors who lack satisfactory alternatives and cannot enroll in formal clinical trials. No efficacy, safety, or outcome data are reported in this registry entry.
Expanded Access. Non Small Cell Lung Cancer, ALK-positive Non-small Cell Lung Cancer (NSCLC); age from 18 Years. Intervention: NVL-655. 48 sites across 12 countries.
This is a registry record for an expanded access program (compassionate use pathway) offering investigational neladalkib to patients with ALK-positive advanced NSCLC or other ALK-positive solid tumors who lack satisfactory alternatives and cannot enroll in formal clinical trials. No efficacy, safety, or outcome data are reported in this registry entry.
No primary endpoints, safety assessments, or outcome measures are defined in this entry. No efficacy, toxicity, or clinical outcome data are available; program status and participant experience are not disclosed.
This registry record documents access to an investigational agent outside formal trials; it contains no efficacy or safety data and does not support clinical decision-making. Clinicians should refer to published trials or regulatory guidance for evidence on neladalkib efficacy and safety.
This is a clinical trial registry record describing an expanded access program with no results reported; it documents planned access to an investigational drug for patients who cannot enroll in formal trials.
As stated by the source record.
Quoted from the source exactly as published.
This registry record documents access to an investigational agent outside formal trials; it contains no efficacy or safety data and does not support clinical decision-making. Clinicians should refer to published trials or regulatory guidance for evidence on neladalkib efficacy and safety.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no key findings. That is a gap in the analysis, not a judgement about the study.
Registry record from ClinicalTrials.gov (NCT06834074). This is a study registration, not published results. Lead sponsor: Nuvalent Inc.. Recruitment status: AVAILABLE. Study type: EXPANDED_ACCESS. Conditions: Non Small Cell Lung Cancer, ALK-positive Non-small Cell Lung Cancer (NSCLC). Interventions: DRUG: NVL-655. Brief summary: The Expanded Access Program will provide an alternate mechanism for patients, who lack satisfactory therapeutic alternatives and cannot participate in a neladalkib clinical trial, to access investigational neladalkib.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.